SELLAS Life Sciences Group 将来の成長

Future 基準チェック /56

SELLAS Life Sciences Groupは、63.5%と67.2%でそれぞれ年率63.5%で利益と収益が成長すると予測される一方、EPSはgrowで64.5%年率。

主要情報

63.5%

収益成長率

64.45%

EPS成長率

Biotechs 収益成長	25.5%
収益成長率	67.2%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	13 May 2026

今後の成長に関する最新情報

Recent updates

分析記事 • Oct 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

分析記事 • Jun 25

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

分析記事 • Nov 23

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

SELLAS Life Sciences (NASDAQ:SLS) is trading 9.2% higher on Tuesday after the company announced results from preclinical studies for its CDK9 inhibitor, GFH009, to treat solid cancer and acute myeloid leukemia (AML) cell lines. The drug showed significant anti-tumor effects in all four selected cell lines, and in three out of the four cell lines, GFH009 inhibited cancer cell growth by 90% to 100%. The following cell lines were selected for the studies: RH30: a pediatric soft tissue sarcoma cell line. NCI-H209: a small cell lung cancer cell line. SKOV-3: an ovarian cancer cell line. OCI-AML-2: an AML cell line. "The data from preclinical studies that we are reporting today demonstrates that certain cancer cell lines, whose survival depends on specific changes in the cell, can be identified and treated with GFH009," said Dragan Cicic, Senior Vice President, Clinical Development, of SELLAS.

業績と収益の成長予測

NasdaqCM:SLS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	102	-8	N/A	N/A	1
12/31/2027	44	-27	N/A	N/A	1
12/31/2026	N/A	-37	N/A	N/A	1
3/31/2026	N/A	-29	-28	-28	N/A
12/31/2025	N/A	-27	-28	-28	N/A
9/30/2025	N/A	-26	-31	-31	N/A
6/30/2025	N/A	-26	-31	-31	N/A
3/31/2025	N/A	-27	-34	-34	N/A
12/31/2024	N/A	-31	-35	-35	N/A
9/30/2024	N/A	-32	-33	-33	N/A
6/30/2024	N/A	-34	-35	-32	N/A
3/31/2024	N/A	-36	-36	-30	N/A
12/31/2023	N/A	-37	-37	-31	N/A
9/30/2023	N/A	-38	-37	-32	N/A
6/30/2023	N/A	-36	-33	-31	N/A
3/31/2023	N/A	-36	-33	-29	N/A
12/31/2022	1	-41	-28	-24	N/A
9/30/2022	1	-39	-28	-24	N/A
6/30/2022	1	-39	-28	-24	N/A
3/31/2022	3	-35	-23	-23	N/A
12/31/2021	8	-21	-26	-26	N/A
9/30/2021	10	-18	-18	-18	N/A
6/30/2021	10	-15	-15	-15	N/A
3/31/2021	8	-15	-14	-14	N/A
12/31/2020	2	-17	-10	-10	N/A
9/30/2020	N/A	-21	-18	-18	N/A
6/30/2020	N/A	-28	-18	-18	N/A
3/31/2020	N/A	-27	-19	-19	N/A
12/31/2019	N/A	-28	N/A	-18	N/A
9/30/2019	N/A	-34	N/A	-18	N/A
6/30/2019	N/A	-32	N/A	-28	N/A
3/31/2019	N/A	-36	N/A	-30	N/A
12/31/2018	N/A	-41	N/A	-30	N/A
9/30/2018	N/A	-37	N/A	-28	N/A
6/30/2018	N/A	-32	N/A	-16	N/A
3/31/2018	N/A	-30	N/A	-13	N/A
12/31/2017	N/A	-24	N/A	-11	N/A
9/30/2017	N/A	-21	N/A	-14	N/A
6/30/2017	N/A	-23	N/A	-16	N/A
3/31/2017	N/A	-20	N/A	-14	N/A
12/31/2016	N/A	-18	N/A	-12	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SLSは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。

収益対市場: SLS今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: SLS今後 3 年以内に収益を上げることが予想されます。

収益対市場: SLSの収益 ( 67.2% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: SLSの収益 ( 67.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SLSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/05/21 23:26
終値	2026/05/21 00:00
収益	2026/03/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

SELLAS Life Sciences Group, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。4

アナリスト	機関
James Molloy	Alliance Global Partners
Aydin Huseynov	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

SELLAS Life Sciences Group 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Forecast to breakeven in 2028

No longer forecast to breakeven

Price target decreased by 17% to US$5.83

Consensus EPS estimates fall by 19%

Consensus EPS estimates upgraded to US$0.87 loss

Recent updates

No longer forecast to breakeven

SELLAS Life Sciences Approaches Key AML Trial Results With Strengthened Cash Position and New Phase 2 Study

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 16, 2026

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Profitability

Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML

Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Forecast to breakeven in 2028

New minor risk - Share price stability

Independent Director recently bought US$101k worth of stock

Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 Programs

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without Modification

Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy Study

SELLAS Life Sciences Group, Inc. Appoints Linghua Wang to Scientific Advisory Board

New minor risk - Share price stability

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

New minor risk - Profitability

Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory Board

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AML

SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR Conference

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 17, 2025

SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual Meeting

SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.

New minor risk - Share price stability

Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML

SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Price target decreased by 17% to US$5.83

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

Consensus EPS estimates fall by 19%

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity